Related Experiment Video
Updated: Feb 8, 2026

Multifocal Electroretinograms
Published on: December 4, 2011
Characteristics and outcomes of progressive multifocal leukoencephalopathy in hematologic malignancies and stem cell
Diego Adrianzen Herrera1, Sabarish Ayyappan2, Sakshi Jasra1
1a Department of Medical Oncology, Albert Einstein College of Medicine/Montefiore Medical Center , Bronx , NY , USA.
Abstract:
Progressive multifocal leukoencephalopathy (PML) is a life-threatening opportunistic infection of immunomodulatory therapies. PML cases reported in PubMed (1995-2017) following stem-cell transplantation (HSCT) or chemoimmunotherapy (CIT) for hematologic malignancies were reviewed. We found 107 cases, 40% were HSCT recipients (32 allogeneic, 11 autologous) and 40% indolent lymphomas receiving monoclonal antibodies (mAbs). HSCT cases had longer time to PML diagnosis (10.8 vs. 4 months, p < .001), higher proportion of PML therapy response (58% vs. 25%, p = .019), lower mortality rate (56% vs. 88%, p < .001), and longer median survival (8 vs. 2 months, p < .001). Outcome differences might be caused by selection bias as HSCT patients are most likely treated aggressively; however, time-dependent immune reconstitution might also contribute to their better prognosis. Increased use of mAbs and HSCT are associated with rising PML incidence in hematological malignancies, currently constituting the second largest vulnerable population after HIV-infected patients; further research is needed for its optimal treatment.
Insights
Progressive multifocal leukoencephalopathy (PML) is a serious risk following stem-cell transplants or chemoimmunotherapy for blood cancers. Patients undergoing stem-cell transplantation generally experience better outcomes and survival rates compared to those receiving other treatments.
Area of Science:
- Neurology
- Infectious Diseases
- Hematology
Background:
- Progressive multifocal leukoencephalopathy (PML) is a rare but severe opportunistic infection affecting the brain.
- It is a known complication of certain immunomodulatory therapies, particularly in patients with hematologic malignancies.
- Understanding PML incidence and outcomes in this population is crucial for patient management.
Observation:
- A review of 107 PML cases between 1995-2017 revealed patients undergoing stem-cell transplantation (HSCT) and those treated with monoclonal antibodies (mAbs) for hematologic malignancies.
- HSCT recipients represented 40% of cases, as did patients with indolent lymphomas receiving mAbs.
- PML diagnosis occurred later in HSCT recipients (10.8 months vs. 4 months).
Findings:
- HSCT recipients showed a higher response rate to PML therapy (58% vs. 25%) and a lower mortality rate (56% vs. 88%) compared to other treatment groups.
- Median survival was significantly longer for HSCT recipients (8 months vs. 2 months).
- These outcome differences may be influenced by patient selection bias and immune reconstitution post-HSCT.
Implications:
- The rising incidence of PML in hematologic malignancies, linked to increased use of mAbs and HSCT, positions this group as the second most vulnerable after HIV-infected patients.
- Further research is essential to optimize treatment strategies and improve prognosis for PML in these immunocompromised individuals.
- The findings highlight the need for vigilant monitoring and proactive management of PML in patients undergoing intensive therapies for blood cancers.
Related Concept Videos
Characteristics of Series Resonant Circuit
Induced Pluripotent Stem Cells
Characteristics of Life
Adult Stem Cells
Embryonic Stem Cells
Outcomes of Glycolysis
Cellular respiration can occur aerobically (with oxygen) or anaerobically (without oxygen). In the presence of oxygen, cellular respiration starts with glycolysis and continues with pyruvate...

